GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of ...

The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...

GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting: London, UK Wednesday, October 9, 2024, 14:0 ...

London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...

RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots.

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.

PHILADELPHIA, PA, USA I October 08, 2024 I GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III ...

Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...

On a similar front, 3% of U.S. high school students surveyed in 2023 identified as transgender, and 25% of transgender ...

A study of long-term care facilities found residents with penicillin allergies were 95% less likely to receive beta-lactam ...

GSK said Wednesday that it is paying up to $2.2 billion to resolve 93% of its US state-based liability cases related to its ...